Executive Summary: Cell Culture: The World Market for Media, Sera, and Reagents

Kalorama Information Executive Summaries
January 1, 2007
17 Pages - SKU: KLE1467862
License type:
Countries covered: Global

Kalorama Information's Executive Summaries provide a comprehensive overview of the contents contained in our full-length market intelligence reports.

Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market.

The report from which this Executive Summary is compiled is Cell Culture: The World Market for Media, Sera, and Reagents , and the full study abstract is as follows:

In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals.

This report is focused on cell culture used in the research and production of biopharmaceuticals, analyzing the world cell culture market and the major trends driving this market in three specific segments:

  • Media,
  • Sera, and
  • Reagents

In addition to a thorough discussion of the technologies and techniques currently employed and emerging in the cell culture area, the Kalorama's exhaustive report provides specific information on:

  • Market Size, growth, and forecasts of the segments through 2011
  • Competitive Market Share by leading supplier as of 2005.
  • Estimated Market Share by Media Type (this is not available in other reports)
  • Key Market Drivers and Restraints for suppliers, including discussions of biopharmaceutical pipelines, seasonal vaccine production, biomedical R&D directions, and the future of transgenic plant and animal production.
  • Review of the various expression systems (Bacteria, Yeast, Insect, and Mammal) and the biopharmaceutical product manufactured by these systems
  • Discussion of the trends and preferences in media types vying for dominance in the market, including the following:
    • ADCF - animal derived component free media
    • CD - chemically defined media
    • CSFM - complete serum free medium
    • PF - protein free media
    • SF - serum free media
    • SFM - serum free medium
  • Profiles of 28 leading suppliers and information about M&A activities since 2003.



More Global Biopharmaceuticals Reports

Global Biosimilars Market Forecast to 2015 by RNCOS
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, ...

Biosimilars: Current Situation & Future Prospects, Worldwide by JustPharmaReports.com
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with ...

World Biological Drugs Market 2012-2022 by Visiongain
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. Our new study ...

Global Biosimilars: A return to optimism? by Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for ...

Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition by Kalorama Information
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent ...

See all reports like this >>